Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 141 of 1,261
  1. US 11883359

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  2. US 11882920

    Systems, devices and methods for styling hair

    MIRAKEL TECHNOLOGIES, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  3. US 11885861

    3-dimensional representations of post-contrast enhanced brain lesions

    The Board of Regents of the University of Texas System · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  4. US 11884932

    In vitro production of medial ganglionic eminence precursor cells

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  5. US 11884945

    Methods for purification of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  6. US 11885807

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  7. US 11884746

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  8. US 11884925

    Synthetic immunomodulation with a CRISPR super-repressor in vivo

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  9. US 11884920

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11883535

    Liposomal particles, methods of making same and uses thereof

    Northwestern University · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  11. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  12. US 11884657

    PI-kinase inhibitors with anti-infective activity

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  13. US 11884656

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  14. US 11883441

    Compositions and methods for inhibiting seizures

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  15. US 11883432

    Chimeric antigen receptor system with adaptable receptor specificity

    Century Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  16. US 11883223

    Hepatic inflammation analysis with dynamic PET

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  17. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  18. US 11883381

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  19. US 11885806

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  20. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  21. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  22. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  23. US 11884647

    Compounds and methods for targeting pathogenic blood vessels

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  24. CA 3262048

    CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF

    SANOFI SA [FR] · Granted Jan 25, 2024 · Expires Jan 20, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.